Hua Er Jie Jian Wen·2026-01-20 09:43Core Viewpoint - The company and its subsidiary have received approval from the National Medical Products Administration for two drug clinical trial notifications, which will commence shortly [1] Drug Details - Injection SHR-9839 (sc) - Indication: Advanced colorectal cancer - Mechanism: Humanized antibody that simultaneously blocks two key tumor signaling pathways - Progress: Initiating Phase Ib/II clinical study in combination with anti-tumor therapy - Competitive Landscape: One drug targeting the same pathway has been approved globally - Cumulative R&D Investment: Approximately 93.9 million [1] - HRS-4642 Injection - Indication: KRAS G12D mutation tumors - Mechanism: KRAS G12D inhibitor (liposome formulation) - Competitive Landscape: No similar drugs have been approved for marketing domestically or internationally - Cumulative R&D Investment: Approximately 254.2 million [1]